Biotech
Arbor Biotechnologies
Arbor Biotechnologies raises $215M Series C at $800M valuation
$215M
Total Raised
Series C
Latest Round
2016
Founded
100+
Employees
830 Winter Street, Waltham, MA 02451
1 min read
Quick Facts
Valuation
$800M
Latest Round Size
$215M
Latest Round Date
November 2024
Arbor Biotechnologies: Series C Funding Round
Arbor Biotechnologies has successfully raised $215M in Series C funding, reaching a valuation of $800M.
Company Overview
Gene editing technologies
Funding Details
The Series C round was led by Lightspeed Venture Partners, with participation from Redmile Group, Agent Capital, Amplitude Ventures.
Company Information
- Headquarters: 830 Winter Street, Waltham, MA 02451
- Founded: 2016
- Employees: 100+
- Category: Biotech
Investment
Arbor Biotechnologies plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Lightspeed Venture Partners: Verified investor in Series C
- Redmile Group: Verified investor in Series C
- Agent Capital: Verified investor in Series C
- Amplitude Ventures: Verified investor in Series C
Key Investors
Lightspeed Venture Partners
Lead Investor
Verified investor in Series C
Redmile Group
Investor
Verified investor in Series C
Agent Capital
Investor
Verified investor in Series C
Amplitude Ventures
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M